165 related articles for article (PubMed ID: 21042412)
1. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.
Accordi B; Espina V; Giordan M; VanMeter A; Milani G; Galla L; Ruzzene M; Sciro M; Trentin L; De Maria R; te Kronnie G; Petricoin E; Liotta L; Basso G
PLoS One; 2010 Oct; 5(10):e13552. PubMed ID: 21042412
[TBL] [Abstract][Full Text] [Related]
2. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
3. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
[TBL] [Abstract][Full Text] [Related]
4. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
Accordi B; Galla L; Milani G; Curtarello M; Serafin V; Lissandron V; Viola G; te Kronnie G; De Maria R; Petricoin EF; Liotta LA; Indraccolo S; Basso G
Leukemia; 2013 Apr; 27(5):1019-27. PubMed ID: 23228943
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
7. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
[TBL] [Abstract][Full Text] [Related]
9. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
[TBL] [Abstract][Full Text] [Related]
10. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
11. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS; Hoogkamer AQ; Ariës IM; Steeghs EMP; Boer JM; Besselink NJM; Boeree A; van de Ven C; de Groot-Kruseman HA; de Haas V; Horstmann MA; Escherich G; Zwaan CM; Cuppen E; Koudijs MJ; Pieters R; den Boer ML
Leukemia; 2018 Apr; 32(4):931-940. PubMed ID: 28972594
[TBL] [Abstract][Full Text] [Related]
12. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW; Catallo R; Chebel A; Baranger L; Thomas X; Béné MC; Gerland LM; Schmidt A; Beldjord K; Klein N; Escoffre-Barbe M; Leguay T; Huguet F; Larosa F; Hayette S; Plesa A; Ifrah N; Dombret H; Salles G; Chassevent A; Ffrench M
Leuk Res; 2015 Apr; 39(4):453-61. PubMed ID: 25675863
[TBL] [Abstract][Full Text] [Related]
13. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
[TBL] [Abstract][Full Text] [Related]
14. High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.
Iqbal Z; Akhtar T; Awan T; Aleem A; Sabir N; Rasool M; Absar M; Akram AM; Shammas MA; Shah IH; Khalid M; Taj AS; Jameel A; Alanazi A; Gill AT; Hashmi JA; Hussain A; Sabar MF; Khalid AM; Qazi MH; Karim S; Siddiqi MH; Mahmood A; Iqbal M; Saeed A; Irfan MI
Mol Diagn Ther; 2015 Oct; 19(5):277-87. PubMed ID: 26266519
[TBL] [Abstract][Full Text] [Related]
15. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
16. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.
Schroeder MP; Bastian L; Eckert C; Gökbuget N; James AR; Tanchez JO; Schlee C; Isaakidis K; Häupl B; Baum K; Migueles Lozano OA; Kouidri K; Pan KT; Urlaub H; Schwartz S; Burmeister T; von Stackelberg A; Hoelzer D; Pfeiffer H; Rieger MA; Göllner S; Oellerich T; Horstman M; Schrappe M; Wolf J; Kirschner-Schwabe R; Brüggemann M; Müller-Tidow C; Serve H; Neumann M; Baldus CD
Sci Rep; 2019 Mar; 9(1):4188. PubMed ID: 30862934
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
19. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
20. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
